294 related articles for article (PubMed ID: 1316775)
21. Comparison of a new tumour marker CA 242 with CA 19-9, CA 50 and carcinoembryonic antigen (CEA) in digestive tract diseases.
Kuusela P; Haglund C; Roberts PJ
Br J Cancer; 1991 Apr; 63(4):636-40. PubMed ID: 2021550
[TBL] [Abstract][Full Text] [Related]
22. High serum concentrations of sialyl Tn antigen in carcinomas of the biliary tract and pancreas.
Nanashima A; Yamaguchi H; Nakagoe T; Matsuo S; Sumida Y; Tsuji T; Sawai T; Yamaguchi E; Yasutake T; Ayabe H
J Hepatobiliary Pancreat Surg; 1999; 6(4):391-5. PubMed ID: 10664288
[TBL] [Abstract][Full Text] [Related]
23. Evaluation of CEA, CA 19-9, CA-50, CA-195, and TATI with special reference to pancreatic disorders.
Masson P; Pålsson B; Andren-Sandberg A
Int J Pancreatol; 1991 May; 8(4):333-44. PubMed ID: 1791319
[TBL] [Abstract][Full Text] [Related]
24. Novel serum tumor marker, RCAS1, in pancreatic diseases.
Yamaguchi K; Enjoji M; Nakashima M; Nakamuta M; Watanabe T; Tanaka M
World J Gastroenterol; 2005 Sep; 11(33):5199-202. PubMed ID: 16127752
[TBL] [Abstract][Full Text] [Related]
25. Tumour marker antigen CA125 in pancreatic cancer: a comparison with CA19-9 and CEA.
Haglund C
Br J Cancer; 1986 Dec; 54(6):897-901. PubMed ID: 3467786
[TBL] [Abstract][Full Text] [Related]
26. Serum testosterone:dihydrotestosterone ratio and CA 19-9 in the diagnosis of pancreatic cancer.
Robles-Díaz G; Díaz-Sánchez V; Fernández-del Castillo C; Morales M; Aceves G; Galván E; Altamirano A
Am J Gastroenterol; 1991 May; 86(5):591-4. PubMed ID: 2028950
[TBL] [Abstract][Full Text] [Related]
27. The possibility of diagnosing small pancreatic cancer (less than 4.0 cm) by measuring various serum tumor markers. A retrospective study.
Satake K; Chung YS; Umeyama K; Takeuchi T; Kim YS
Cancer; 1991 Jul; 68(1):149-52. PubMed ID: 2049735
[TBL] [Abstract][Full Text] [Related]
28. The diagnostic value of CA 27-29, CA 15-3, mucin-like carcinoma antigen, carcinoembryonic antigen and CA 19-9 in breast and gastrointestinal malignancies.
Frenette PS; Thirlwell MP; Trudeau M; Thomson DM; Joseph L; Shuster JS
Tumour Biol; 1994; 15(5):247-54. PubMed ID: 7991985
[TBL] [Abstract][Full Text] [Related]
29. Evaluation of Tumor Markers and Their Impact on Prognosis in Gallbladder, Bile Duct and Cholangiocellular Carcinomas - A Pilot Study.
Liska V; Treska V; Skalicky T; Fichtl J; Bruha J; Vycital O; Topolcan O; Palek R; Rosendorf J; Polivka J; Holubec L
Anticancer Res; 2017 Apr; 37(4):2003-2009. PubMed ID: 28373474
[TBL] [Abstract][Full Text] [Related]
30. Comparative evaluation of serum CA 195 and carcinoembryonic antigen in metastatic carcinoma.
Verdi CJ; Ahmann FR; Schifman RB; Elvick AL; Ahmann ME; Marx PC
Cancer; 1993 Jun; 71(11):3625-32. PubMed ID: 8490911
[TBL] [Abstract][Full Text] [Related]
31. Comparison of CA19-9 with other tumor markers in the diagnosis of cancer of the pancreas.
Satake K; Takeuchi T
Pancreas; 1994 Nov; 9(6):720-4. PubMed ID: 7846015
[TBL] [Abstract][Full Text] [Related]
32. CA 242 is a new tumor marker for pancreatic cancer.
Röthlin MA; Joller H; Largiadèr F
Cancer; 1993 Feb; 71(3):701-7. PubMed ID: 8431849
[TBL] [Abstract][Full Text] [Related]
33. [Value of plasma testosterone, carcinoembryonic antigen and CA 19-9 in the differential diagnosis of pancreatic carcinoma and chronic pancreatitis].
Jurkowska G; Kulpa J; Skrodzka D; Rogowski F
Pol Arch Med Wewn; 1992 Nov; 88(5):302-9. PubMed ID: 1300550
[TBL] [Abstract][Full Text] [Related]
34. Roles of serum and biliary CEA, CA19-9, VEGFR3, and TAC in differentiating between malignant and benign biliary obstructions.
Ince AT; Yıldız K; Baysal B; Danalıoğlu A; Kocaman O; Tozlu M; Gangarapu V; Sarbay Kemik A; Uysal Ö; Şentürk H
Turk J Gastroenterol; 2014 Apr; 25(2):162-9. PubMed ID: 25003676
[TBL] [Abstract][Full Text] [Related]
35. Serum CA 242 in pancreatic cancer. Comparison with CA 19-9 and CEA.
Pezzilli R; Billi P; Plate L; Laudadio MA; Sprovieri G
Ital J Gastroenterol; 1995; 27(6):296-9. PubMed ID: 8562994
[TBL] [Abstract][Full Text] [Related]
36. A multicentre evaluation of tumour marker determinations using the automatic Enzymun-Test Systems ES 300 and ES 600/700.
van Dalen A; Kessler AC
Eur J Clin Chem Clin Biochem; 1996 Apr; 34(4):377-84. PubMed ID: 8704058
[TBL] [Abstract][Full Text] [Related]
37. Comparison of serum CA 19-9 and CEA levels in a population at high risk for colorectal cancer.
Goldberg EM; Simunovic LM; Drake SL; Mueller WF; Verrill HL
Hybridoma; 1989 Oct; 8(5):569-75. PubMed ID: 2807313
[TBL] [Abstract][Full Text] [Related]
38. Serum CA242, CA199, CA125, CEA, and TSGF are Biomarkers for the Efficacy and Prognosis of Cryoablation in Pancreatic Cancer Patients.
Chen Y; Gao SG; Chen JM; Wang GP; Wang ZF; Zhou B; Jin CH; Yang YT; Feng XS
Cell Biochem Biophys; 2015 Apr; 71(3):1287-91. PubMed ID: 25486903
[TBL] [Abstract][Full Text] [Related]
39. Serum CYFRA 21-1 in Biliary Tract Cancers: A Reliable Biomarker for Gallbladder Carcinoma and Intrahepatic Cholangiocarcinoma.
Huang L; Chen W; Liang P; Hu W; Zhang K; Shen S; Chen J; Zhang Z; Chen B; Han Y; Meng F; DeMorrow S; Yin X; Lai J; Liang L
Dig Dis Sci; 2015 May; 60(5):1273-83. PubMed ID: 25487191
[TBL] [Abstract][Full Text] [Related]
40. Serum CA 242: the search for a valid marker of pancreatic cancer.
Ventrucci M; Ubalducci GM; Cipolla A; Panella MA; Ligabue A
Clin Chem Lab Med; 1998 Mar; 36(3):179-84. PubMed ID: 9589807
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
